Abstract：
Sporadic or hereditary medullary thyroid carcinoma (MTC) is an uncommon thyroid malignancy arising from calcitonin secreting parafollicular C cells. Interestingly, MTC and calcitonin were distinct entities that were discovered independently yet concurrently, and their association was unknown.
This review aims to present a historical review of the evolution of our understanding of MTC and its tumor marker calcitonin to highlight the prominent individuals that influenced and shaped our knowledge of this uncommon thyroid cancer type up to the dawn of the 21st century. An overview of all published reports of novel research and work summarizing important findings for MTC and calcitonin was carried out.
Surgery remains the cornerstone of treatment for localized MTC. However, several new treatment options are either available or in development for advanced or metastatic MTC, including several novel small molecules targeting oncogenic RET and peptide receptor radionuclide therapy, immunotherapy, radioimmunotherapy, and radiofrequency ablation. In the near future, these novel treatments hold promise for therapy of this very distinct thyroid cancer type.
This review aims to present a historical review of the evolution of our understanding of MTC and its tumor marker calcitonin to highlight the prominent individuals that influenced and shaped our knowledge of this uncommon thyroid cancer type up to the dawn of the 21st century. An overview of all published reports of novel research and work summarizing important findings for MTC and calcitonin was carried out.
Surgery remains the cornerstone of treatment for localized MTC. However, several new treatment options are either available or in development for advanced or metastatic MTC, including several novel small molecules targeting oncogenic RET and peptide receptor radionuclide therapy, immunotherapy, radioimmunotherapy, and radiofrequency ablation. In the near future, these novel treatments hold promise for therapy of this very distinct thyroid cancer type.
摘要：
散发性或遗传性甲状腺髓样癌（MTC）是一种罕见的甲状腺恶性肿瘤，由分泌降钙素的滤泡旁C细胞引起。有趣的是,MTC和降钙素是独立发现但同时发现的不同实体，他们的联系是未知的。
这篇综述旨在对我们对MTC及其肿瘤标志物降钙素的理解的演变进行历史回顾，以突出影响和塑造我们对21世纪初这种罕见甲状腺癌类型的认识的杰出个体。对总结MTC和降钙素的重要发现的新研究和工作的所有已发表报告进行了概述。
手术仍然是治疗局部MTC的基石。然而,对于晚期或转移性MTC，有几种新的治疗方案可用或正在开发中，包括几种靶向致癌RET和肽受体放射性核素治疗的新型小分子，免疫疗法，放射免疫疗法,和射频消融.在不久的将来,这些新颖的治疗方法有望治疗这种非常独特的甲状腺癌。
这篇综述旨在对我们对MTC及其肿瘤标志物降钙素的理解的演变进行历史回顾，以突出影响和塑造我们对21世纪初这种罕见甲状腺癌类型的认识的杰出个体。对总结MTC和降钙素的重要发现的新研究和工作的所有已发表报告进行了概述。
手术仍然是治疗局部MTC的基石。然而,对于晚期或转移性MTC，有几种新的治疗方案可用或正在开发中，包括几种靶向致癌RET和肽受体放射性核素治疗的新型小分子，免疫疗法，放射免疫疗法,和射频消融.在不久的将来,这些新颖的治疗方法有望治疗这种非常独特的甲状腺癌。
